Covered recipient · General Payments record
STEVEN WESLEY PIPE
Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$303,788.20
159 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $136,839.01 | 40 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $94,348.16 | 43 |
| Travel and Lodging | $69,075.15 | 41 |
| Food and Beverage | $2,528.88 | 34 |
| Education | $997.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| BioMarin Pharmaceutical Inc. | $71,415.16 | 32 |
| CSL Behring | $50,453.81 | 35 |
| GENZYME CORPORATION | $41,670.81 | 27 |
| SANOFI-AVENTIS U.S. LLC | $36,495.12 | 9 |
| Roche Products Limited | $33,637.88 | 8 |
| Ultragenyx Pharmaceutical Inc. | $17,627.27 | 5 |
| HEMA Biologics, LLC | $13,892.79 | 15 |
| PFIZER INC. | $12,913.25 | 10 |
| Novo Nordisk Health Care AG | $6,545.00 | 4 |
| SANOFI US SERVICES INC. | $5,538.00 | 1 |
| Regeneron Pharmaceuticals, Inc. | $4,974.00 | 3 |
| Chugai Pharmaceutical Co., Ltd. | $3,818.45 | 2 |
| Genentech USA, Inc. | $2,806.66 | 7 |
| Samsung Bioepis Co., Ltd. | $2,000.00 | 1 |
Page 3 of 4; records 101–150 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
STEVEN WESLEY PIPE
NPI 1255341889 · CMS profile ID 192992
Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology
ANN ARBOR, MI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1255341889?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- STEVEN WESLEY PIPE, NPI 1255341889, CMS profile ID 192992. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255341889?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). STEVEN WESLEY PIPE, NPI 1255341889, CMS profile ID 192992. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255341889?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- STEVEN WESLEY PIPE, NPI 1255341889, CMS profile ID 192992, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1255341889?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
159 matching records · $303,788.20 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 159.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc. | $13.40 | 05/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127062710 | CMS |
| BioMarin Pharmaceutical Inc. | $3,150.00 | 05/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127062888 | CMS |
| HEMA Biologics, LLC | $154.85 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820981 | CMS |
| BioMarin Pharmaceutical Inc. | $84.10 | 04/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127060960 | CMS |
| GENZYME CORPORATION | $250.00 | 04/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621583 | CMS |
| GENZYME CORPORATION | $500.00 | 04/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621591 | CMS |
| GENZYME CORPORATION | $250.00 | 04/21/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621581 | CMS |
| GENZYME CORPORATION | $500.00 | 04/21/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621585 | CMS |
| PFIZER INC. | $25.11 | 04/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132115067 | CMS |
| Genentech USA, Inc. | $44.62 | 04/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133117837 | CMS |
| Regeneron Pharmaceuticals, Inc. | $2,487.00 | 04/12/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114403757 | CMS |
| HEMA Biologics, LLC | $86.80 | 04/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820979 | CMS |
| CSL Behring | $219.90 | 04/05/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134646471 | CMS |
| BioMarin Pharmaceutical Inc. | $674.00 | 03/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127062708 | CMS |
| HEMA Biologics, LLC | $13.99 | 03/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820971 | CMS |
| Novo Nordisk Health Care AG | $3,570.00 | 03/24/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1096553784 | CMS |
| HEMA Biologics, LLC | $5,000.00 | 03/23/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820959 | CMS |
| HEMA Biologics, LLC | $132.99 | 03/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820963 | CMS |
| HEMA Biologics, LLC | $5.87 | 03/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820969 | CMS |
| HEMA Biologics, LLC | $224.73 | 03/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820989 | CMS |
| HEMA Biologics, LLC | $57.26 | 03/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820991 | CMS |
| HEMA Biologics, LLC | $116.86 | 03/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820997 | CMS |
| HEMA Biologics, LLC | $88.15 | 03/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820999 | CMS |
| HEMA Biologics, LLC | $127.56 | 03/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152821005 | CMS |
| CSL Behring | $438.90 | 03/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134646469 | CMS |
| HEMA Biologics, LLC | $14.52 | 03/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820955 | CMS |
| Ultragenyx Pharmaceutical Inc. | $412.86 | 03/15/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153281481 | CMS |
| BioMarin Pharmaceutical Inc. | $4,275.00 | 03/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127057507 | CMS |
| PFIZER INC. | $2,000.00 | 03/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131629481 | CMS |
| Regeneron Pharmaceuticals, Inc. | $829.00 | 03/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114403753 | CMS |
| Regeneron Pharmaceuticals, Inc. | $1,658.00 | 03/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114403755 | CMS |
| HEMA Biologics, LLC | $869.21 | 03/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152820975 | CMS |
| GENZYME CORPORATION | $11,468.00 | 02/27/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621611 | CMS |
| GENZYME CORPORATION | $87.41 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621613 | CMS |
| GENZYME CORPORATION | $25.80 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621615 | CMS |
| GENZYME CORPORATION | $72.46 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621617 | CMS |
| GENZYME CORPORATION | $156.93 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621619 | CMS |
| GENZYME CORPORATION | $572.70 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621621 | CMS |
| GENZYME CORPORATION | $355.35 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621623 | CMS |
| GENZYME CORPORATION | $1,024.38 | 02/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621625 | CMS |
| BioMarin Pharmaceutical Inc. | $1,800.00 | 02/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127062486 | CMS |
| Novo Nordisk Health Care AG | $1,785.00 | 02/22/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1096553792 | CMS |
| GENZYME CORPORATION | $250.00 | 02/09/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621553 | CMS |
| Genentech USA, Inc. | $121.68 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133117833 | CMS |
| CSL Behring | $616.60 | 02/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134646467 | CMS |
| Ultragenyx Pharmaceutical Inc. | $545.49 | 01/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153281307 | CMS |
| CSL Behring | $571.61 | 01/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134646385 | CMS |
| GENZYME CORPORATION | $12,946.98 | 01/20/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621637 | CMS |
| GENZYME CORPORATION | $86.80 | 01/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139621639 | CMS |
| PFIZER INC. | $750.00 | 01/19/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131311634 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $12,977.61 | 19 |
| PY2025 | Principal investigator | $339,468.04 | 96 |
| PY2024 | Recipient | $20,047.93 | 14 |
| PY2024 | Principal investigator | $301,630.34 | 79 |
| PY2023 | Recipient | $14,674.20 | 12 |
| PY2023 | Principal investigator | $219,416.86 | 44 |
| PY2022 | Recipient | $5,264.27 | 7 |
| PY2022 | Principal investigator | $254,458.25 | 40 |
| PY2021 | Recipient | $14,471.22 | 8 |
| PY2021 | Principal investigator | $317,985.11 | 38 |
| PY2020 | Recipient | $32,283.78 | 15 |
| PY2020 | Principal investigator | $350,462.29 | 47 |
| PY2019 | Recipient | $648.26 | 2 |
| PY2019 | Principal investigator | $437,068.33 | 68 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
115 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | CSL Behring | $146.97 | 12/30/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670438 |
| Principal investigator 1 | CSL Behring | $200.56 | 12/24/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies | No dispute reported | 06/30/2026 | 1252670436 |
| Principal investigator 1 | CSL Behring | $18.00 | 12/24/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670614 |
| Principal investigator 1 | CSL Behring | $7,130.50 | 12/19/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670494 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,461.65 | 12/19/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138919 |
| Recipient | GENZYME CORPORATION | $500.00 | 12/08/2025 | Covered Recipient Physician | ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX | No dispute reported | 06/30/2026 | 1226096416 |
| Recipient | GENZYME CORPORATION | $500.00 | 12/06/2025 | Covered Recipient Physician | An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | No dispute reported | 06/30/2026 | 1226096410 |
| Principal investigator 1 | CSL Behring | $7,336.00 | 12/05/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670568 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $176.83 | 12/04/2025 | Covered Recipient Physician | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184121507 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $303.43 | 12/04/2025 | Covered Recipient Physician | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184121509 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $81.27 | 12/04/2025 | Covered Recipient Physician | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184121511 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $39.28 | 12/04/2025 | Covered Recipient Physician | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184121513 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $112.42 | 12/04/2025 | Covered Recipient Physician | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184121515 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $39.28 | 12/04/2025 | Covered Recipient Physician | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184121517 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $102.94 | 12/04/2025 | Covered Recipient Physician | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184121519 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $138.60 | 12/03/2025 | Covered Recipient Physician | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184121505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $732.00 | 11/20/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A PROSPECTIVE STUDY TO EVALUATE DISEASE CHARACTERISTICS IN HEMOPHILIA B PARTICIPANTS RECEIVING PROPHYLAXIS WITH STANDARD OF CARE FIX REPLACEMENT THERAPY | No dispute reported | 06/30/2026 | 1184138847 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $322.00 | 11/20/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138849 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $645.00 | 11/20/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138851 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,818.15 | 11/20/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138853 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $542.00 | 11/20/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138855 |
| Principal investigator 1 | CSL Behring | $600.00 | 11/05/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670560 |
| Principal investigator 1 | CSL Behring | $750.00 | 11/05/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670562 |
| Principal investigator 1 | CSL Behring | $812.70 | 11/05/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670564 |
| Recipient | GENZYME CORPORATION | $250.00 | 11/03/2025 | Covered Recipient Physician | An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | No dispute reported | 06/30/2026 | 1226096421 |
| Recipient | GENZYME CORPORATION | $250.00 | 11/03/2025 | Covered Recipient Physician | ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX | No dispute reported | 06/30/2026 | 1226096427 |
| Principal investigator 1 | CSL Behring | $14,639.95 | 10/21/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies | No dispute reported | 06/30/2026 | 1252670492 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $600.00 | 10/16/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | BMN 270-401 | No dispute reported | 06/30/2026 | 1248578964 |
| Principal investigator 1 | CSL Behring | $3,800.00 | 10/10/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670488 |
| Principal investigator 1 | CSL Behring | $5,456.00 | 10/10/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670490 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $434.64 | 10/10/2025 | Covered Recipient Physician | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184121503 |
| Principal investigator 1 | CSL Behring | $74.75 | 10/08/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670612 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,311.44 | 10/03/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138641 |
| Principal investigator 1 | CSL Behring | $2,521.00 | 10/02/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670484 |
| Principal investigator 1 | CSL Behring | $2,834.90 | 10/02/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies | No dispute reported | 06/30/2026 | 1252670486 |
| Principal investigator 1 | Genentech, Inc. | $6,060.49 | 09/24/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | No dispute reported | 06/30/2026 | 1211559814 |
| Principal investigator 1 | CSL Behring | $697.00 | 09/18/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670482 |
| Principal investigator 1 | CSL Behring | $466.59 | 09/18/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies | No dispute reported | 06/30/2026 | 1252670610 |
| Principal investigator 1 | Genentech, Inc. | $3,096.00 | 09/12/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | No dispute reported | 06/30/2026 | 1211559819 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,229.00 | 09/12/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138611 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $644.00 | 09/12/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138613 |
| Principal investigator 1 | CSL Behring | $1,625.40 | 09/03/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670544 |
| Principal investigator 1 | CSL Behring | $1,935.00 | 09/03/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670546 |
| Principal investigator 1 | CSL Behring | $2,100.00 | 09/03/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670548 |
| Principal investigator 1 | CSL Behring | $3,500.00 | 09/03/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670550 |
| Principal investigator 1 | CSL Behring | $1,935.00 | 09/03/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670572 |
| Principal investigator 1 | CSL Behring | $270.90 | 08/27/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670526 |
| Principal investigator 1 | CSL Behring | $645.00 | 08/27/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670528 |
| Principal investigator 1 | CSL Behring | $1,300.00 | 08/27/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670530 |
| Principal investigator 1 | CSL Behring | $1,612.00 | 08/27/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670532 |
| Principal investigator 1 | CSL Behring | $4,000.00 | 08/27/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670534 |
| Principal investigator 1 | CSL Behring | $9,675.00 | 08/27/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670536 |
| Principal investigator 1 | CSL Behring | $20,000.00 | 08/27/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670538 |
| Principal investigator 1 | CSL Behring | $23,000.00 | 08/27/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670540 |
| Principal investigator 1 | CSL Behring | $18.00 | 08/25/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670608 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,907.92 | 08/14/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138453 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $1,883.00 | 08/06/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | BMN 270-401 | No dispute reported | 06/30/2026 | 1248578962 |
| Principal investigator 1 | CSL Behring | $899.90 | 07/30/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies | No dispute reported | 06/30/2026 | 1252670480 |
| Principal investigator 1 | CSL Behring | $542.00 | 07/23/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670478 |
| Principal investigator 1 | CSL Behring | $19,799.00 | 07/14/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670476 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,913.07 | 07/10/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A PROSPECTIVE STUDY TO EVALUATE DISEASE CHARACTERISTICS IN HEMOPHILIA B PARTICIPANTS RECEIVING PROPHYLAXIS WITH STANDARD OF CARE FIX REPLACEMENT THERAPY | No dispute reported | 06/30/2026 | 1184138419 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,600.00 | 07/10/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A PROSPECTIVE STUDY TO EVALUATE DISEASE CHARACTERISTICS IN HEMOPHILIA B PARTICIPANTS RECEIVING PROPHYLAXIS WITH STANDARD OF CARE FIX REPLACEMENT THERAPY | No dispute reported | 06/30/2026 | 1184138421 |
| Principal investigator 1 | CSL Behring | $1,289.00 | 07/09/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670474 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,659.02 | 07/04/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138405 |
| Principal investigator 1 | CSL Behring | $750.00 | 06/25/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670472 |
| Principal investigator 1 | CSL Behring | $337.05 | 06/25/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670606 |
| Principal investigator 1 | Genentech, Inc. | $3,839.00 | 06/25/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | No dispute reported | 06/30/2026 | 1211559794 |
| Principal investigator 1 | CSL Behring | $108.33 | 06/17/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670602 |
| Principal investigator 1 | CSL Behring | $78.73 | 06/17/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies | No dispute reported | 06/30/2026 | 1252670604 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $890.10 | 06/16/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | BMN 270-401 | No dispute reported | 06/30/2026 | 1248578960 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,753.34 | 06/12/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138381 |
| Principal investigator 1 | CSL Behring | $6,254.95 | 06/04/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies | No dispute reported | 06/30/2026 | 1252670470 |
| Principal investigator 1 | CSL Behring | $1,239.00 | 06/03/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670468 |
| Principal investigator 1 | Genentech, Inc. | $3,928.00 | 06/03/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | No dispute reported | 06/30/2026 | 1211559799 |
| Principal investigator 1 | Genentech, Inc. | $14,029.00 | 06/03/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | No dispute reported | 06/30/2026 | 1211559803 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $2,083.00 | 05/30/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | BMN 270-401 | No dispute reported | 06/30/2026 | 1248578958 |
| Principal investigator 1 | CSL Behring | $1,128.46 | 05/28/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects ( 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670600 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,782.94 | 05/28/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138371 |
| Principal investigator 1 | CSL Behring | $18.00 | 05/27/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670598 |
| Principal investigator 1 | CSL Behring | $36.00 | 05/23/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670596 |
| Principal investigator 1 | CSL Behring | $134.00 | 05/22/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670594 |
| Principal investigator 1 | CSL Behring | $7,446.00 | 05/16/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670466 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,445.20 | 05/15/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138355 |
| Principal investigator 1 | CSL Behring | $2,834.90 | 05/14/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies | No dispute reported | 06/30/2026 | 1252670464 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,891.47 | 05/08/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138257 |
| Recipient | F. Hoffmann-La Roche AG | $1,040.00 | 05/07/2025 | Covered Recipient Physician | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | No dispute reported | 06/30/2026 | 1211539102 |
| Recipient | F. Hoffmann-La Roche AG | $534.00 | 05/07/2025 | Covered Recipient Physician | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | No dispute reported | 06/30/2026 | 1211539106 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,870.00 | 05/02/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138251 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $483.00 | 05/02/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138253 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,458.00 | 05/02/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138255 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $534.53 | 04/28/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A PROSPECTIVE STUDY TO EVALUATE DISEASE CHARACTERISTICS IN HEMOPHILIA B PARTICIPANTS RECEIVING PROPHYLAXIS WITH STANDARD OF CARE FIX REPLACEMENT THERAPY | No dispute reported | 06/30/2026 | 1184138239 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,088.84 | 04/28/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138241 |
| Principal investigator 1 | CSL Behring | $116.00 | 04/24/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B | No dispute reported | 06/30/2026 | 1252670462 |
| Principal investigator 1 | CSL Behring | $32.10 | 04/23/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670592 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,891.47 | 04/23/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138219 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $5,780.22 | 04/20/2025 | Covered Recipient Physician | HEMEB CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121501 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,615.19 | 04/15/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138201 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,752.22 | 04/08/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138197 |
| Principal investigator 1 | CSL Behring | $897.00 | 04/02/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670458 |
| Principal investigator 1 | CSL Behring | $1,289.00 | 04/02/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | No dispute reported | 06/30/2026 | 1252670460 |
| Principal investigator 1 | Genentech, Inc. | $3,775.00 | 04/01/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | No dispute reported | 06/30/2026 | 1211559806 |
| Recipient | F. Hoffmann-La Roche AG | $1,040.00 | 03/31/2025 | Covered Recipient Physician | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | No dispute reported | 06/30/2026 | 1211539110 |
| Principal investigator 1 | Genentech, Inc. | $3,573.00 | 03/26/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | No dispute reported | 06/30/2026 | 1211559810 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,369.55 | 03/25/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138187 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $30,858.81 | 03/19/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138175 |
| Principal investigator 1 | CSL Behring | $899.90 | 03/14/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies | No dispute reported | 06/30/2026 | 1252670456 |
| Principal investigator 1 | CSL Behring | $433.63 | 03/12/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies | No dispute reported | 06/30/2026 | 1252670590 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $721.28 | 02/19/2025 | Covered Recipient Physician | HEMEB CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121499 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $3,409.47 | 02/14/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | BMN 270-401 | No dispute reported | 06/30/2026 | 1248578954 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $5,502.00 | 02/14/2025 | Covered Recipient Teaching Hospital Univ Of Mi Hospitals & Hlth Ctrs | BMN 270-401 | No dispute reported | 06/30/2026 | 1248578956 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,935.00 | 02/11/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138003 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $813.00 | 02/11/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138005 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $483.00 | 02/11/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B | No dispute reported | 06/30/2026 | 1184138007 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,325.00 | 02/11/2025 | Covered Recipient Teaching Hospital UNIV OF MI HOSPITALS & HLTH CTRS | A PROSPECTIVE STUDY TO EVALUATE DISEASE CHARACTERISTICS IN HEMOPHILIA B PARTICIPANTS RECEIVING PROPHYLAXIS WITH STANDARD OF CARE FIX REPLACEMENT THERAPY | No dispute reported | 06/30/2026 | 1184138009 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $933.42 | 01/10/2025 | Covered Recipient Physician | HEMEB CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121497 |